Table 2.
Baseline characteristics of studies in carbapenem-resistant P. aeruginosa
| Author | Year | Design | Country | Case/Exposure | Control/Comparator | Total N | Age cases (Yr) | Age control (Yr) | Male cases (%) | Male control (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| D’Agata (a) [17] | 2006 | CC, matched | USA, Italy | CRPA | Non-P. aeruginosa | 82 | 61 | 60 | 73 | 44 |
| DalBen [42] | 2013 | P, cohort | Brazil | MRAC and CRPA | Non-MRAC and non-CRPA | 325 | 44 | 41 | 59 | 41 |
| Djordjevic [43] | 2013 | P, cohort | Serbia | CRPA | CSPA | 261 | 59.2 | 61.4 | 80.8 | 64.9 |
| Eagye (a) [44] | 2009 | CC, control | USA | MRPA | MSPA | 183 | 66.4 | 66.1 | 58.6 | 59.2 |
| Eagye (b) [44] | 2009 | CC, control | USA | MRPA | Non-P. aeruginosa | 182 | 66.4 | 57.4 | 58.6 | 50.9 |
| Fortaleza (a) [45] | 2006 | CC, matched | Brazil | IRPA | Control (NR) | 324 | median 45 | median 44 | 68.5 | 60.2 |
| Furtado [46] | 2009 | CC, matched | Brazil | IRPA | Without IRPA | 245 | 50 | 54 | 68.3 | 59.3 |
| Furtado [47] | 2010 | CC, matched | Brazil | IRPA | Non-IRPA | 295 | 54 | 54 | 70.7 | 56.5 |
| Harris [50] | 2002 | CC, matched | USA | IRPA | Without IRPA | 866 | 55.7 | 49.4 | 39.1 | 39.1 |
| Harris [51] | 2011 | P, cohort | USA | IRPA | Non-IRPA | 3146 | 56.7 | 55.7 | 61.9 | 56.7 |
| Kohlenberg [54] | 2010 | CC, unmatched | Germany | CRPA | CSPA | 33 | median 60 | median 44.4 | 53.3 | 72.2 |
| Lautenbach [55] | 2010 | CC, unmatched | USA | IRPA | ISPA | 2542 | 61 (total) | 61 (total) | 63.3 | 56.1 |
| Lee [56] | 2015 | CC, matched | Taiwan | CRPA | All susceptible P. aeruginosa | 75 | 61.6 | 62 | 48 | 48 |
| Lin [57] | 2016 | CC, unmatched | Taiwan | CRPA | CSPA | 164 | 66.6 | 63.5 | 72 | 67.1 |
| Luyt [58] | 2014 | P, cohort | France | CRPA | CSPA | 169 | 57.6 | 57.9 | 65 | 66 |
| Onguru [59] | 2008 | P, cohort | Turkey | IRPA | ISPA | 170 | 45.9 | 49.7 | 72 | 66.3 |
| Pena [60] | 2007 | P, cohort | Spain | CRPA | CSPA | 254 | 59.8 | 57.1 | 60 | 65 |
| Pereira [61] | 2008 | CC, unmatched | Brazil | IRPA | ISPA | 59 | 51.8 | 50.7 | 70 | 55 |
| Tam [62] | 2007 | CC, unmatched | USA | CRPA | Pan-susceptible P. aeruginosa | 51 | 50 | 64 | 33 | 73 |
| Tuon [40] | 2012 | CC, unmatched | Brazil | CRPA | CSPA | 77 | 46.4 | 49 | 75.9 | 70.8 |
| Zavascki (a) [64] | 2005 | CC, unmatched | Brazil | IRPA | Non P. aeruginosa | 186 | 58 | 51 | 60 | 53 |
| Zavascki (b) [64] | 2005 | CC, unmatched | Brazil | IRPA | ISPA | 158 | 58 | 51 | 60 | 66 |
| Zhang [65] | 2009 | CC, unmatched | China | CRPA | CSPA | 34 | 61 | 50 | NR | NR |
CC case-control, CRPA carbapenem-resistantP. aeruginosa, CSPA carbapenem-susceptible P.aeruginosa, ICU Intensive Care Unit, IRPA imipenem-resistant P. aeruginosa, ISPA imipenem-susceptible P.aeruginosa, MRAC meropenem-resistant Acinetobacter baumannii, MRPA meropenem-resistant P. aeruginosa, MSPA meropenem-susceptible P. aeruginosa, NR not reported,k P parallel, SICU Surgical Intensive Care Unit, YR year